Can you take Cervarix with Dimethyl fumarate?

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Dehydration.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a major potential interaction with Fever.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Hypotension.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Immunodeficiency.

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

Dimethyl fumarate has a moderate potential interaction with Immunodeficiency.

Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability. Caution and monitoring are advised in patients with MS. Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.

The human papillomavirus vaccine in Cervarix has a major potential interaction with Infection.

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

Dimethyl fumarate has a moderate potential interaction with Infection.

The use of dimethyl fumarate may decrease lymphocyte counts. Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients. CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated. Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered. Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.

Dimethyl fumarate has a moderate potential interaction with Infection.

Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate. Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections. Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment. Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.

Dimethyl fumarate has a moderate potential interaction with Liver Disease.

Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients. Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting. Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation. Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials. Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated. Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.

Dimethyl fumarate has a moderate potential interaction with Lymphocytopenia.

The use of dimethyl fumarate may decrease lymphocyte counts. Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients. CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated. Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered. Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.

Dimethyl fumarate has a moderate potential interaction with Renal Dysfunction.

Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.

The human papillomavirus vaccine in Cervarix has a moderate potential interaction with Syncope.

The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury. The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity. Caution is recommended when administering the vaccine to individuals susceptible to syncope. Observation for 15 minutes is recommended after its administration.